NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free CLSD Stock Alerts $1.31 -0.04 (-3.22%) (As of 09:57 AM ET) Add Compare Share Share Today's Range$1.28▼$1.3150-Day Range$1.15▼$2.0252-Week Range$0.65▼$2.12Volume45,765 shsAverage Volume312,317 shsMarket Capitalization$97.62 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Clearside Biomedical alerts: Email Address Clearside Biomedical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside251.9% Upside$4.75 Price TargetShort InterestHealthy0.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.02Based on 5 Articles This WeekInsider TradingAcquiring Shares$56,388 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.56) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector543rd out of 915 stocksPharmaceutical Preparations Industry250th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has only been the subject of 4 research reports in the past 90 days.Read more about Clearside Biomedical's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.36% of the outstanding shares of Clearside Biomedical have been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 18.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLSD. Previous Next 1.7 News and Social Media Coverage News SentimentClearside Biomedical has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Clearside Biomedical this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows6 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,388.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions.Read more about Clearside Biomedical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to grow in the coming year, from ($0.56) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad OIC[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. Click here to register now (5/15 Webinar) About Clearside Biomedical Stock (NASDAQ:CLSD)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Read More CLSD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLSD Stock News HeadlinesMay 7, 2024 | insidertrades.com3 Penny Stocks That Insiders Are Buying (CLSD)May 10, 2024 | markets.businessinsider.comBuy Rating on Clearside Biomedical: Anticipating ODYSSEY Trial Success and Market Growth PotentialMay 10, 2024 | OIC (Ad)[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. May 9, 2024 | globenewswire.comClearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences ConferenceMay 2, 2024 | americanbankingnews.comClearside Biomedical (NASDAQ:CLSD) Shares Cross Below 50-Day Moving Average of $1.45May 2, 2024 | americanbankingnews.comClearside Biomedical (CLSD) Set to Announce Quarterly Earnings on ThursdayApril 30, 2024 | globenewswire.comClearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024May 10, 2024 | OIC (Ad)[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. April 21, 2024 | seekingalpha.comCLSD Clearside Biomedical, Inc.April 16, 2024 | globenewswire.comClearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of DirectorsApril 2, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 18, 2024 | globenewswire.comClearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical OfficerMarch 14, 2024 | markets.businessinsider.comClearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial ProgressMarch 14, 2024 | finance.yahoo.comClearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong FinancialsMarch 13, 2024 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | benzinga.comClearside Biomedical: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comClearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...March 12, 2024 | globenewswire.comClearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | benzinga.comPreview: Clearside Biomedical's EarningsMarch 1, 2024 | finance.yahoo.comClearside Biomedical, Inc. (CLSD)February 29, 2024 | globenewswire.comClearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024February 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 21, 2024 | markets.businessinsider.comModivCare is about to announce its earnings — here's what Wall Street expectsFebruary 21, 2024 | benzinga.comClearside Biomedical Stock (NASDAQ:CLSD), Short Interest ReportFebruary 18, 2024 | finance.yahoo.comCLSD Apr 2024 5.000 callSee More Headlines Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/10/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSD CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+251.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,490,000.00 Net Margins-394.91% Pretax Margin-394.91% Return on EquityN/A Return on Assets-85.31% Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio4.42 Sales & Book Value Annual Sales$8.23 million Price / Sales12.26 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-5.40Miscellaneous Outstanding Shares74,721,000Free Float67,398,000Market Cap$100.87 million OptionableOptionable Beta2.35 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. George M. Lasezkay J.D. (Age 72)Pharm.D., Pharma.D., President, CEO & Director Comp: $816.4kMr. Charles A. Deignan (Age 60)Chief Financial Officer Comp: $536.95kDr. Thomas A. Ciulla M.B.A. (Age 59)M.D., Chairman of Scientific Advisory Board Comp: $597.21kMs. Jenny R. Kobin (Age 57)Head of Investor Relations Mr. Rick McElhenyVice President of Corporate DevelopmentMr. Rafael V. Andino (Age 59)Senior Vice President of Engineering & Manufacturing Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerDr. Ngai Hang Chong M.B.A.M.D., Chief Medical OfficerMr. Leslie B. Zacks (Age 55)Secretary More ExecutivesKey CompetitorsEton PharmaceuticalsNASDAQ:ETONAclaris TherapeuticsNASDAQ:ACRSOramed PharmaceuticalsNASDAQ:ORMPAnixa BiosciencesNASDAQ:ANIXMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCBought 32,270 shares on 5/7/2024Ownership: 0.043%Rosalind Advisors Inc.Bought 2,592,593 shares on 4/25/2024Ownership: 3.470%Anthony S GibneyBought 6,710 shares on 4/17/2024Total: $8,387.50 ($1.25/share)International Assets Investment Management LLCBought 36,000 shares on 4/11/2024Ownership: 0.048%Ngai Hang Victor ChongBought 30,000 shares on 3/20/2024Total: $48,000.00 ($1.60/share)View All Insider TransactionsView All Institutional Transactions CLSD Stock Analysis - Frequently Asked Questions Should I buy or sell Clearside Biomedical stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks. What is Clearside Biomedical's stock price target for 2024? 4 brokers have issued 12-month target prices for Clearside Biomedical's shares. Their CLSD share price targets range from $4.00 to $6.00. On average, they expect the company's share price to reach $4.75 in the next year. This suggests a possible upside of 251.9% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. How have CLSD shares performed in 2024? Clearside Biomedical's stock was trading at $1.17 at the start of the year. Since then, CLSD shares have increased by 15.4% and is now trading at $1.35. View the best growth stocks for 2024 here. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its earnings results on Tuesday, March, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The firm had revenue of $6.35 million for the quarter, compared to the consensus estimate of $3.40 million. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Rosalind Advisors Inc. (3.47%), International Assets Investment Management LLC (0.05%), SG Americas Securities LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony S Gibney, Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Ngai Hang Victor Chong, Richard T Burke and Thomas Ciulla. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLSD) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
